Similar Papers

Paper Title
Journal
Date
Author
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Mark T Reding ... Maria Elisa Mancuso
Drugs in R&D | VOL. 24
Mark T Reding, et. al.Mark T Reding ... Maria Elisa Mancuso
20 Aug 2024
Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A
Alexander Solms ... Toshko Lissitchkov
Blood | VOL. 136
Alexander Solms, et. al.Alexander Solms ... Toshko Lissitchkov
05 Nov 2020
PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety.
Andreas Baumann
Haemophilia | VOL. 26
Andreas BaumannAndreas Baumann
19 Nov 2019
Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset
Martin Chandler ... Michael Recht
Blood | VOL. 140
Martin Chandler, et. al.Martin Chandler ... Michael Recht
15 Nov 2022
View more papers

More From: Drugs in R&D

Paper Title
Journal
Date
Author
Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug Therapy.
Xiaolin Xu ... Huawei Mao
Drugs in R&D | VOL. -
Xiaolin Xu, et. al.Xiaolin Xu ... Huawei Mao
11 Apr 2025
Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar.
Herve Bischoff ... Pierre Coliat
Drugs in R&D | VOL. -
Herve Bischoff, et. al.Herve Bischoff ... Pierre Coliat
02 Apr 2025
A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database.
Yi Yin ... Youpeng Jin
Drugs in R&D | VOL. -
Yi Yin, et. al.Yi Yin ... Youpeng Jin
21 Jan 2025
Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases.
Diana Dubrall ... Bernhardt Sachs
Drugs in R&D | VOL. -
Diana Dubrall, et. al.Diana Dubrall ... Bernhardt Sachs
21 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.